Product image of Inspra (Eplerenone) supplied by GNH India

Inspra

Active Ingredient:
Eplerenone
Origin:
EU

Inspra (Eplerenone)

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It reduces sodium and water retention while preserving potassium, and is prescribed to manage hypertension and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release and comprehensive regulatory documentation.

Manufacturer / TM Owner

Viatris Hellas Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Eplerenone is a mineralocorticoid receptor antagonist used in cardiovascular disease management.

  • Hypertension: lowers blood pressure by reducing sodium and water retention.
  • Heart failure with reduced ejection fraction: improves survival and reduces hospitalizations by decreasing cardiac remodeling.
  • Post‑myocardial infarction: helps prevent heart failure progression and reduces risk of cardiovascular events.

How It Works

  • Eplerenone selectively blocks the binding of aldosterone to mineralocorticoid receptors in the distal nephron and cardiovascular tissues. By antagonizing this receptor, it inhibits sodium reabsorption and potassium excretion, leading to natriuresis and diuresis, and attenuates aldosterone‑mediated myocardial fibrosis and vascular remodeling. The resulting electrolyte balance reduces fluid overload, while the anti‑fibrotic effect contributes to improved cardiac function over time in patients.

Side Effects

Eplerenone may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Hyperkalemia: elevated blood potassium levels.
  • Dizziness: light‑headed sensation, especially on standing.
  • Headache: mild to moderate intensity.
  • Fatigue: feeling of tiredness or reduced energy.
  • Diarrhea: loose stools.
  • Cough: non‑productive respiratory irritation.

Serious or Rare Side Effects

  • Severe hyperkalemia: potentially life‑threatening potassium excess.
  • Acute kidney injury: sudden decline in renal function.
  • Gynecomastia: breast tissue enlargement in males.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Allergic reactions: rash, itching, or anaphylaxis.

Precautions & Warnings

When prescribing eplerenone, clinicians should consider several safety precautions to minimize risk.

  • Renal function: assess baseline kidney function and monitor regularly.
  • Serum potassium: check potassium levels before initiation and during therapy.
  • Concomitant drugs: avoid use with potassium‑sparing diuretics or ACE inhibitors without monitoring.
  • Pregnancy: contraindicated; avoid use in pregnant women.
  • Breastfeeding: not recommended due to potential infant exposure.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Avoid Interactions

Eplerenone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia.
  • ACE inhibitors or ARBs: combined use increases risk of hyperkalemia and renal impairment.
  • NSAIDs: can reduce renal clearance and exacerbate potassium retention.

Moderate Interactions (Monitor Closely)

  • Digoxin: increased serum levels may occur.
  • Antifungal agents (e.g., ketoconazole): may raise eplerenone concentrations.
  • Beta‑blockers: may enhance antihypertensive effect, requiring blood pressure monitoring.

Frequently Asked Questions

Inspra contains eplerenone, a mineralocorticoid receptor antagonist indicated for the treatment of hypertension, heart failure with reduced ejection fraction, and for management after a myocardial infarction to help prevent progression of heart failure.

Eplerenone selectively blocks aldosterone from binding to mineralocorticoid receptors in the kidney and cardiovascular tissue. This antagonism reduces sodium reabsorption and potassium loss, promoting fluid excretion and decreasing cardiac remodeling associated with excess aldosterone.

The dose of Inspra is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s clinical condition, renal function, and serum potassium levels. No fixed regimen is provided here.

Inspra is contraindicated in pregnancy because mineralocorticoid receptor antagonists can affect fetal development. It is also not recommended while breastfeeding, as the drug may pass into breast milk and could affect the infant.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative is spironolactone, a non‑selective mineralocorticoid antagonist. Eplerenone (Inspra) is more selective for the aldosterone receptor, resulting in fewer endocrine side effects such as gynecomastia, but both share similar efficacy in lowering blood pressure and managing heart failure.

Inspra tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Inspra is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or split unless specifically advised by a healthcare professional.

The most serious risks include hyperkalemia, which can be life‑threatening, and acute kidney injury. Patients should have regular monitoring of serum potassium and renal function, especially when combined with other drugs that affect potassium balance.

Inspra should not be used by individuals with severe hyperkalemia, significant renal impairment, or those who are pregnant. Caution is also advised for patients with hepatic disease or those taking other potassium‑sparing medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.